Concentration-effect relation of succinylcholine chloride during propofol anesthesia

Anesthesiology

Volumn 97, Issue 5, 2002, Pages 1082-1092

  Roy, Julie J ^a   Donati, Francois ^a   Boismenu, Daniel ^b   Varin, France ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PROPOFOL; REMIFENTANIL; SUXAMETHONIUM; VECURONIUM;

ADULT; ANESTHESIA; ANESTHESIA INDUCTION; ARTERIAL BLOOD; ARTICLE; BOLUS INJECTION; CLINICAL ARTICLE; COMPARTMENT MODEL; CORRELATION ANALYSIS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONCENTRATION; DRUG DEGRADATION; DRUG ELIMINATION; DRUG HYDROLYSIS; DRUG POTENCY; FEMALE; HUMAN; MALE; MUSCLE CONTRACTION; MUSCLE TWITCH; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL;

ADULT; ANESTHETICS, INTRAVENOUS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROMUSCULAR DEPOLARIZING AGENTS; PROPOFOL; SUCCINYLCHOLINE;

EID: 0036840246     PISSN: 00033022     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000542-200211000-00009     Document Type: Article

References (46)

1. Whittaker V, Wijesundera S: The hydrolysis of succinylcholine by cholinesterase. Biochem J 1952;52:475-9
2. Viby-Mogensen J, Hanel HK: Prolonged apnoea after suxamethonium: An analysis of the first 225 cases reported to the Danish Cholinesterase Research Unit. Acta Anaesthesiol Scand 1978; 22:371-80
3. Ducharme J, Varin F, Bevan DR, Donati F: Importance of early blood sampling on vecuronium pharmacokinetic and pharmacodynamic parameters. Clin Pharmacokinet 1993; 24:507-18
4. Runciman WB, Upton RN: Pharmacokinetics and pharmacodynamics: What is of value to the practising anaesthetist? Anaesthetic pharmacol Rev 1994; 2:280-93
5. Hoshi K, Hashimoto Y, Matsukawa S: Pharmacokinetics of succinylcholine in man. Tohuku J Exp Med 1993; 170:245-50
6. Roy JJ, Boismenu D, Gao H, Mamer OA, Varin F: Measurement of succinyl-choline concentration in human plasma by electrospray tandem mass spectrometry. Anal Biochem 2001; 290:238-45
7. Koelle G, Steiner E: The cerebral distributions of a tertiary and a quaternary anticholinesterase agent following intravenous and intraventricular injection. J Pharmacol Exp Ther 1956; 118:420-34
8. Longpre J: [Qualitative and quantitative measurement of the activity of pseudocholinesterases]. Can J Med Technol 1971; 33:213-27
9. Hartley HO: The modified Gauss-Newton method for fitting of non-linear regression functions by least squares. Technometrics 1961; 3:269-80
10. Davies M, Whitting IJ: A Modified Form of Levenberg's Correction, Numerical Methods For Non-Linear Optimization Edited by Lootsma FA. London, Academic Press, 1972, pp 191-201
11. Gibaldi M, Perrier D: Pharmacokinetics. Edited by Gibaldi M, Perrier D. New York, Marcel Dekker, 1982, pp 1-494
12. Nakashima E, Benet LZ: General treatment of mean residence time, clearance, and volume parameters in linear mammillary models with elimination from any compartment. J Pharmacokinet Biopharm 1988; 16:475-92
13. Laurin J, Nekka F, Donati F, Varin F: Assuming peripheral elimination: Its impact on the estimation of pharmacokinetic parameters of muscle relaxants. J Pharmacokinet Biopharm 1999; 27:491-512
14. Yamaoka K, Nakagawa T, Uno T: Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm 1978; 6:165-75
15. Ezzine S, Donati F, Varin F: Aterial-venous gradient under mivacurium steady-state concentrations in anesthetized patients (abstract). Anesthesiology 2001; 95:A468
16. Jacquez JA: Compartmental analysis in biology and medicine. Edited by Jacquez JA. Ann Arbor. BioMedware, 1996, pp 1-514
17. Unadkat JD, Bartha F, Sheiner LB: Simultaneous modeling of pharmacokinetics and pharmacodynamics with nonparametric kinetic and dynamic models. Clin Pharmacol Ther 1986; 40:86-93
18. Sheiner LB, Stanski DR, Vozeh S, Miller RD, Ham J: Simultaneous modeling of pharmacokinetics and pharmacodynamics: Application to d-tubocurarine. Clin Pharmacol Ther 1979; 25:358-71
19. Fuseau E, Sheiner LB: Simultaneous modeling of pharmacokinetics and pharmacodynamics with a nonparametric pharmacodynamic model. Clin Pharmacol Ther 1984; 35:733-41
20. Holford NH, Sheiner LB: Understanding the dose-effect relationship: Clinical application of pharmacokinetic-pharmacodynamic models. Clin Pharmacokinet 1981; 6:429-53
21. Weiss M: Errors in clearance estimation after bolus injection and arterial sampling: Nonexistence of a central compartment. J Pharmacokinet Biopharm 1997; 2:255-60
22. Zhu Y, Audibert G, Donati F, Varin F: Pharmacokinetic pharmacodynamic modeling of doxacurium: Effect of input rate. J Pharmacokinet Biopharm 1997; 25:23-37
23. Lacroix M, Donati F, Varin F: Pharmacokinetics of mivacurium isomers and their metabolites in healty volunteers after intravenous bolus administration. Anesthesiology 1997; 86:322-30
24. Viby-Mogensen J, Engbaek J, Eriksson LI, Gramstad L, Jensen E, Jensen FS, Koscielniak-Nielsen Z, Skovgaard LT, Ostergaard D: Good clinical research practice (GCRP) in pharmacodynamic studies of neuromuscular blocking agents. Acta Anaesthesiol Scand 1996; 40:59-74
25. Foldes FF: Enzymes of acetylcholine metabolism. Enzymes in Anesthesiology. Edited by Foldes FF. New York, Springer-Verlag, 1978, pp 91-168
26. Rosenberg MK, Lebenbom-Mansour M: Markedly prolonged paralysis after mivacurium in a patient apparently heterozygous for the atypical and usual pseudocholinesterase alleles by conventional biochemical testing. Anesth Analg 1997; 84:457-60
27. Jensen FS, Skovgaard LT, Viby-Mogensen J: Identification of human plasma cholinesterase variants in 6,688 individuals using biochemical analysis. Acta Anaesthesiol Scand 1995; 39:157-62
28. Viby-Mogensen J: Correlation of succinylcholine duration of action with plasma cholinesterase activity in subjects with the genotypically normal enzyme. Anesthesiology 1980; 53:517-20
29. Hickey DR, O'Connor JP, Donati F: Comparison of atracurium and succinylcholine for electroconvulsive therapy in a patient with atypical plasma cholinesterase. Can J Anaesth 1987; 34:280-3
30. Fisher DM, Canfell PC, Fahey MR, Rosen JI, Rupp SM, Sheiner LB, Miller RD: Elimination of atracurium in humans: Contribution of hofman elimination and ester hydrolysis versus organ-based elimination. Anesthesiology 1986; 65: 6-12
31. Welch RM, Brown A, Ravitch J, Dahl R: The in vitro degradation of cisatracurium, the R, cis-R'-isomer of atracurium, in human and rat plasma. Clin Pharmacol Ther 1995; 58:132-42
32. Kisor DF, Schmith VD, Wargin WA, Lien CA, Ornstein E, Cook DR: Importance of the organ-independant elimination of cisatracurium. Anest Analg 1996; 83:1065-71
33. Bergeron L, Bevan DR, Berrill A. Kahwaji R, Varin F: Concentration-effect relationship of cisatracurium at three different dose levels in the anesthetized patient. Anesthesiology 2001; 95:314-23
34. Lien CA, Schmith VD, Belmont MR, Abalos A, Kisor DF, Savarese JJ: Pharmacokinetics of cisatracurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia. Anesthesiology 1996; 84:300-8
35. Krejcie TC, Henthorn TK, Niemann CU, Klein C, Gupta DK, Brooks Gentry W, Shanks CA, Avram MJ: Recirculatory pharmacokinetic models of markers of blood, extracellular fluid and total body water administered concomitanly. J Pharmacol Exp Ther 1996; 278:1050-7
36. Kuipers JA, Boer F, Olofsen E, Bovill JG, Burm AG: Recirculatory pharmacokinetics and pharmacodynamics of rocuronium in patients. Anesthesiology 2001; 94:47-55
37. Dragne A, Varin F, Plaud B, Donati F: Rocuronium pharmacokinetic-pharmacodynamic relationship under propofol and isoflurane anesthesia. Can J Anaesth 2002; 49:353-60
38. Donati F, Gill SS, Bevan DR, Ducharme J, Theoret Y, Varin F: Pharmacokinetics and pharmacodynamics of atracurium with and without previous suxamethonium administration. Br J Anaesth 1991; 66:557-61
39. Laurin J, Donati F, Nekka F, Varin F: Peripheral link model as an alternative for pharmacokinetic-pharmacodynamic modeling of drugs having a very short elimination half-life. J Pharmacokinet Biopharm 2001; 28:7-25
40. Hennis PJ, Stanski DR: Pharmacokinetic and pharmacodynamic factors that govern the clinical use of muscle relaxants. Semin Anesth 1985; 4:21-30
41. Stanski DR, Ham J, Miller RD, Sheiner LB: Pharmacokinetics and pharmacodynamics of d-tubocurarine during nitrous oxide-narcotic and halothane anesthesia in man. Anesthesiology 1979; 51:235-41
42. Ducharme J, Varin F, Donati F: Pharmacokinetics and pharmacodynamics of a second dose of atracurium in anaesthetised patients. Clin Drug Invest 1995; 9:98-110
43. Torda T, Graham G, Warwick N, Donohue P: Pharmacokinetics and pharmacodynamics of suxemethonium. Anaesth Intensive Care 1997; 25:272-8
44. Wright PM, Brown R. Lau M, Fisher DM: A pharmacodynamic explanation for the rapid onset/offset of rapacuronium bromide. Anesthesiology 1999; 90:16-23
45. Beaufort TM, Nigrovic V, Proost JH, Houwertjes MC, Wierda JM: Inhibition of the enzymic degradation of suxamethonium and mivacurium increases the onset time of submaximal neuromuscular block. Anesthesiology 1998; 89:707-14
46. Kopman AF, Klewicka MM, Kopman DJ, Neuman GG: Molar potency is predictive of the speed of onset of neuromuscular block for agents of intermediate, short, and ultrashort duration. Anesthesiology 1999; 90:425-31